To cite this paper use one of the standards below:
The development of resistant strains of Mycobacterium tuberculosis (Mtb) is a big concern, which highlights the need of discovering new antibiotics1. Recent studies investigated molecular targets in earlier steps of peptidoglycan synthesis to discover new drugs for tuberculosis treatment2. These findings led us to select the enzyme UDP-N-acetylenolpyruvoylglucosamine reductase (MurB) due to its essential role in peptidoglycan synthesis and no eukaryote homologue2. Andres and coworkers discovered 4-thiazolidinones as MurB inhibitors at a micromolar level3. This way, we are proposing thiazoline and phthalimide derivatives as MurB inhibitors. Molecular docking studies were performed with MurB4 in complex with the proposed heterocycles with several aromatic substituents (electronic and steric effects) and their precursors, which resulted in more than 150 molecules. Interactions with key residues in MurB catalysis such as Arg176, Glu361 and Ser257 were observed, also theoretical Ki at low micromolar range. These results may guide the discovery of new antibiotics against Mtb.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper